BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30185799)

  • 1. Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
    Gautam J; Banskota S; Lee H; Lee YJ; Jeon YH; Kim JA; Jeong BS
    Exp Mol Med; 2018 Sep; 50(9):1-14. PubMed ID: 30185799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tryptophan hydroxylase 1 and 5-HT
    Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
    Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulation of cathepsin S expression by HSP90 and 5-HT
    Gautam J; Bae YK; Kim JA
    Breast Cancer Res Treat; 2017 Jan; 161(1):29-40. PubMed ID: 27796714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
    Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
    J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ophiopogonin D suppresses TGF-β1-mediated metastatic behavior of MDA-MB-231 breast carcinoma cells via regulating ITGB1/FAK/Src/AKT/β-catenin/MMP-9 signaling axis.
    Zhu X; Wang K; Chen Y
    Toxicol In Vitro; 2020 Dec; 69():104973. PubMed ID: 32818624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylethanolamine-binding protein 4 is associated with breast cancer metastasis through Src-mediated Akt tyrosine phosphorylation.
    Li H; Huang F; Fan L; Jiang Y; Wang X; Li J; Wang Q; Pan H; Sun J; Cao X; Wang X
    Oncogene; 2014 Sep; 33(37):4589-98. PubMed ID: 24276246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating extracellular vesicles from patients with breast cancer enhance migration and invasion via a Src‑dependent pathway in MDA‑MB‑231 breast cancer cells.
    Ramírez-Ricardo J; Leal-Orta E; Martínez-Baeza E; Ortiz-Mendoza C; Breton-Mora F; Herrera-Torres A; Elizalde-Acosta I; Cortes-Reynosa P; Thompson-Bonilla R; Perez Salazar E
    Mol Med Rep; 2020 Sep; 22(3):1932-1948. PubMed ID: 32582965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
    Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
    J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
    Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
    Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Berberine Suppresses Cell Motility Through Downregulation of TGF-β1 in Triple Negative Breast Cancer Cells.
    Kim S; Lee J; You D; Jeong Y; Jeon M; Yu J; Kim SW; Nam SJ; Lee JE
    Cell Physiol Biochem; 2018; 45(2):795-807. PubMed ID: 29414799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BJ-1108, a 6-Amino-2,4,5-Trimethylpyridin-3-ol Analog, Inhibits Serotonin-Induced Angiogenesis and Tumor Growth through PI3K/NOX Pathway.
    Banskota S; Gautam J; Regmi SC; Gurung P; Park MH; Kim SJ; Nam TG; Jeong BS; Kim JA
    PLoS One; 2016; 11(1):e0148133. PubMed ID: 26824764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
    Lou L; Yu Z; Wang Y; Wang S; Zhao Y
    Cancer Sci; 2018 May; 109(5):1648-1659. PubMed ID: 29575318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.
    Hamurcu Z; Delibaşı N; Geçene S; Şener EF; Dönmez-Altuntaş H; Özkul Y; Canatan H; Ozpolat B
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):415-430. PubMed ID: 29288363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
    Wu Q; Ma X; Jin Z; Ni R; Pan Y; Yang G
    J Ethnopharmacol; 2023 Oct; 315():116644. PubMed ID: 37196814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.
    Gari HH; DeGala GD; Ray R; Lucia MS; Lambert JR
    Cancer Lett; 2016 Oct; 380(2):505-512. PubMed ID: 27452906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
    Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
    Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel cystathionine γ-lyase inhibitor, I194496, inhibits the growth and metastasis of human TNBC via downregulating multiple signaling pathways.
    Liu Y; Wang L; Zhang X; Deng Y; Pan L; Li H; Shi X; Wang T
    Sci Rep; 2021 Apr; 11(1):8963. PubMed ID: 33903672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.